Metabolic Risk Factors and Effect of Alirocumab on CV Events

Accumulation of metabolic risk factors substantially increased risk for MACE in patients with recent ACS. Alirocumab treatment reduced MACE consistently, although absolute risk reduction was more pronounced in patients with multiple metabolic risk factors, including patients without diabetes (Ostadal P, et al. [Lancet Diabetes Endocrinol. 2022]).

Login to access this and all our premium content
New to Campus Sanofi? Register to access all our Content